▶ 調査レポート

核医学ラジオアイソトープ(放射性同位体)の世界市場:ラジオアイソトープのタイプ別(テクネチウム-99m(Tc-99m)、タリウム-201(T1-110)、ヨウ素(I-123)、フッ素-18、ルビジウム-82(Rb-82)、ヨウ素-131(I-131)、イットリウム-90(Y-90)、サマリウム-153(Sm-153)、レニウム-186(Re-186)、ルテチウム-177(Lu-177)、ラジウム223(Ra-223)・塩化ラジウム、アクチニウム-225(Ac-225)、鉛-212(Pb-212)・蒼鉛-212(Bi-212)、アスタチン-211(At-211)、ラジウム224(Ra-224)、トリウム-227(Th-227)、セシウム-131、ヨウ素-125、パラジウム-103、イリジウム-192、その他)、用途別(腫瘍、心臓疾患、リンパ腫、甲状腺、神経、その他)、地域別分析

• 英文タイトル:Global Nuclear Medicine Radioisotopes Market - Segmented by type of Radioisotopes, Application and Geography - Growth, Trend and Geography (2018 - 2023)

Mordor Intelligenceが調査・発行した産業分析レポートです。核医学ラジオアイソトープ(放射性同位体)の世界市場:ラジオアイソトープのタイプ別(テクネチウム-99m(Tc-99m)、タリウム-201(T1-110)、ヨウ素(I-123)、フッ素-18、ルビジウム-82(Rb-82)、ヨウ素-131(I-131)、イットリウム-90(Y-90)、サマリウム-153(Sm-153)、レニウム-186(Re-186)、ルテチウム-177(Lu-177)、ラジウム223(Ra-223)・塩化ラジウム、アクチニウム-225(Ac-225)、鉛-212(Pb-212)・蒼鉛-212(Bi-212)、アスタチン-211(At-211)、ラジウム224(Ra-224)、トリウム-227(Th-227)、セシウム-131、ヨウ素-125、パラジウム-103、イリジウム-192、その他)、用途別(腫瘍、心臓疾患、リンパ腫、甲状腺、神経、その他)、地域別分析 / Global Nuclear Medicine Radioisotopes Market - Segmented by type of Radioisotopes, Application and Geography - Growth, Trend and Geography (2018 - 2023) / B-MOR-040904資料のイメージです。• レポートコード:B-MOR-040904
• 出版社/出版日:Mordor Intelligence / 2018年2月
• レポート形態:英文、PDF、103ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:医療・バイオ
• 販売価格(消費税別)
  Single User(1名様用)¥565,250 (USD4,250)▷ お問い合わせ
  Team User(7名様用)¥598,500 (USD4,500)▷ お問い合わせ
  Corporate User¥1,163,750 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、核医学ラジオアイソトープ(放射性同位体)の世界市場について調べ、核医学ラジオアイソトープ(放射性同位体)の世界規模、市場動向、市場環境、ラジオアイソトープのタイプ別(テクネチウム-99m(Tc-99m)、タリウム-201(T1-110)、ヨウ素(I-123)、フッ素-18、ルビジウム-82(Rb-82)、ヨウ素-131(I-131)、イットリウム-90(Y-90)、サマリウム-153(Sm-153)、レニウム-186(Re-186)、ルテチウム-177(Lu-177)、ラジウム223(Ra-223)・塩化ラジウム、アクチニウム-225(Ac-225)、鉛-212(Pb-212)・蒼鉛-212(Bi-212)、アスタチン-211(At-211)、ラジウム224(Ra-224)、トリウム-227(Th-227)、セシウム-131、ヨウ素-125、パラジウム-103、イリジウム-192、その他)分析、用途別(腫瘍、心臓疾患、リンパ腫、甲状腺、神経、その他)分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。
・イントロダクション
・エグゼクティブサマリー
・核医学ラジオアイソトープ(放射性同位体)の世界市場インサイト
・核医学ラジオアイソトープ(放射性同位体)の世界市場環境
・核医学ラジオアイソトープ(放射性同位体)の世界市場動向
・核医学ラジオアイソトープ(放射性同位体)の世界市場規模
・核医学ラジオアイソトープ(放射性同位体)の世界市場規模:ラジオアイソトープのタイプ別(テクネチウム-99m(Tc-99m)、タリウム-201(T1-110)、ヨウ素(I-123)、フッ素-18、ルビジウム-82(Rb-82)、ヨウ素-131(I-131)、イットリウム-90(Y-90)、サマリウム-153(Sm-153)、レニウム-186(Re-186)、ルテチウム-177(Lu-177)、ラジウム223(Ra-223)・塩化ラジウム、アクチニウム-225(Ac-225)、鉛-212(Pb-212)・蒼鉛-212(Bi-212)、アスタチン-211(At-211)、ラジウム224(Ra-224)、トリウム-227(Th-227)、セシウム-131、ヨウ素-125、パラジウム-103、イリジウム-192、その他)
・核医学ラジオアイソトープ(放射性同位体)の世界市場規模:用途別(腫瘍、心臓疾患、リンパ腫、甲状腺、神経、その他)
・核医学ラジオアイソトープ(放射性同位体)の世界市場:地域別市場規模・分析
・核医学ラジオアイソトープ(放射性同位体)の北米市場規模・予測
・核医学ラジオアイソトープ(放射性同位体)のアメリカ市場規模・予測
・核医学ラジオアイソトープ(放射性同位体)のヨーロッパ市場規模・予測
・核医学ラジオアイソトープ(放射性同位体)のアジア市場規模・予測
・核医学ラジオアイソトープ(放射性同位体)の日本市場規模・予測
・核医学ラジオアイソトープ(放射性同位体)の中国市場規模・予測
・核医学ラジオアイソトープ(放射性同位体)のインド市場規模・予測
・核医学ラジオアイソトープ(放射性同位体)の韓国市場規模・予測
・関連企業情報・競争状況

The global nuclear medicine radioisotopes market has been estimated to reach USD 13.9 billion in 2017.The market is expected to register a CAGR of 12.3% during the forecast period 2018 to 2023. North America accounted for the largest market share, for approximately 40% of the global market share in 2017, while Asia-Pacific region was estimated to register the fastest CAGR through the forecast period, 2018-2023.

Rising SPECT and PET Applications

The field of nuclear medicine is dominated by the applications related to positron emission tomography (PET) and single-photon emission computerized tomography (SPECT). Growing interest of PET technology in cardiac and neurological disorders is expected to fuel the market growth. More than 60% of SPECT procedures are performed in cardiology and in addition, orthopedics, oncology and infection imaging are emerging as areas that can benefit from the same. Applications are further increased through the inclusion of advancements in computed tomography (CT), making nuclear medicine as a rising choice for disease diagnosis. In addition, factors such as rising incidences of cardiac and cancer cases along-with rising awareness of public for the same, drives the nuclear medicine market.

High Capital Investments is involved

One of the major hindrance for the nuclear medicine radioisotopes market is the high capital investments required for the generation of radionuclide. Cyclotron initial investment is very high which followed by renovation and installation and further annual operating costs are involved. With high investment, the cost of imaging and treatment overall becomes a factor of high expenditure especially in developing markets. These factors including unclear regulatory guidelines and varied reimbursement policies and short half-life of radiopharmaceuticals restricts the growth of this market.

North America to Dominate this Market

The global nuclear medicine radioisotopes market is segmented by types of radioisotopes, by applications in different indications and geography. Geographically, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa and South America.
North America dominated the nuclear medicine radioisotopes market with approximately 40% of the global market share in 2017. The factors such as well-established healthcare facilities and the rise in geriatric population, with rising awareness among people for nuclear medicine treatments and diagnosis contribute to the growth of this market in the region. Moreover, Asia-Pacific region was estimated to register the fastest CAGR through the forecast period, 2018-2023.

Key Developments in the Market

• December 2017: Caris Life Sciences identified a new mechanism for the treatment of non-Hodgkin lymphoma (NHL) using a single-stranded DNA aptamer, C10.36, specifically binding to heterogeneous nuclear ribonucleoprotein U (hnRNP U).
• October 2017: Siemens Healthcare introduced biograph vision PET/CT system, a software platform at the 30th Annual Congress of the European Association of Nuclear Medicine (EANM), to provide a new level of precision in PET/CT imaging.

Major Players: MEDTRONIC plc, GE HEALTHCARE, LANTHEUS MEDICAL IMAGING inc, HOLOGIC inc, CARDINAL HEALTH inc, BAYER HEALTHCARE ag, BRACCO IMAGING spa, NTP RADIOISOTOPES SOC ltd, POSITRON CORPORATION and SIEMENS HEALTHCARE

Reasons to Purchase the Report

• Market analysis for the Global Nuclear Medicine Radioisotopes Market, with region-specific assessments and competition analysis on a global and regional scale.
• Analyzing various perspectives of the industry with the help of Porter’s five forces analysis.
• The treatment type that is expected to dominate the market.
• Regions that are expected to witness fastest growth during the forecast period.
• Identify the latest developments, market shares and strategies employed by the major market players.
• 3 months analyst support along with the Market Estimate sheet in excel.

Customization of the Report

• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.

レポート目次

1 Introduction
1.1 Market Definition
2 Research Methodology
3 Executive Summary
4 Key Inferences
5 Market Overview
5.1 Current Market Scenario
5.2 Porters Five Forces
5.2.1 Bargaining Power Of Suppliers
5.2.2 Bargaining Power Of Consumers
5.2.3 Threats Of New Entrants
5.2.4 Threat Of Substitute Product And Services
5.2.5 Competitive Rivalry Within The Industry
6 Drivers, Restraints, Opportunities And Challenges Analysis (Droc)
6.1 Market Drivers
6.1.1 Increasing Incidents Of Cancer And Cardiac Ailments
6.1.2 Increasing Spect And Pet Applications
6.1.3 Growing Public Awareness For Healthcare
6.2 Market Constraints
6.2.1 High Capital Investment
6.2.2 Regulatory Guidelines
6.2.3 Reimbursement Issues
6.3 Opportunities
6.4 Threats
7 Market Segmentation
7.1 By Type Of Radioisotopes
7.1.1 Technetium-99m (Tc-99m)
7.1.2 Thallium-201 (Tl-201)
7.1.3 Iodine (I-123)
7.1.4 Fluorine-18
7.1.5 Rubidium-82 (Rb-82)
7.1.6 Iodine-131 (I-131)
7.1.7 Yttrium-90 (Y-90)
7.1.8 Samarium-153 (Sm-153)
7.1.9 Rhenium-186 (Re-186)
7.1.10 Lutetium-177 (Lu-177)
7.1.11 Radium-223 (Ra-223) & Alpharadin
7.1.12 Actinium-225 (Ac-225)
7.1.13 Lead-212 (Pb-212)/Bismuth-212 (Bi-212)
7.1.14 Astatine-211 (At-211)
7.1.15 Radium-224 (Ra-224)
7.1.16 Thorium-227 (Th-227)
7.1.17 Cesium-131
7.1.18 Iodine-125
7.1.19 Palladium-103
7.1.20 Iridium-192
7.1.21 Others
7.2 By Applications
7.2.1 Oncology
7.2.2 Cardiology
7.2.3 Lymphoma
7.2.4 Thyroid
7.2.5 Neurology
7.2.6 Others
7.3 Segmentation By Geography
7.3.1north America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.2.3.4 Italy
7.3.2.5 Spain
7.2.3.6 Rest Of Europe
7.3.3 Asia-Pacific
7.3.3.1china
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia & New Zealand
7.3.3.5 South Korea
7.3.3.6 Rest Of Asia-Pacific
7.3.4 Middle East And Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest Of Middle East And Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest Of South America
8 Competitive Landscape
8.1 Mergers And Acquisition Analysis
8.2 Agreements, Collaborations & Partnerships
8.3 New Products Launches
9 Key Players
9.1 Medtronic Plc
9.2 Ge Healthcare
9.3 Lantheus Medical Imaging Inc
9.4 Hologic Inc
9.5 Cardinal Health Inc
9.6 Bayer Healthcare Ag
9.7 Bracco Imaging Spa
9.8 NTP Radioisotopes Soc Ltd
9.9 Positron Corporation
9.10 Siemens Healthcare
9.11 Others
10 Future Of The Market